Creative Biolabs provides comprehensive Enterococcus faecalis microbiome research services to academic institutes, biotech startups, and pharmaceutical R&D teams. Using advanced microbial isolation, in vitro screening, and host-interaction assays, we help decipher the roles of E. faecalis in the gut microbiome and accelerate the development of microbiome-based solutions.
Creative Biolabs is a globally recognized CRO trusted by industry leaders for high-quality microbiome R&D support.
E. faecalis is a Gram-positive commensal bacterium representing about 1% of the gut microbiota. Although modest in abundance, it plays significant roles: some strains produce bacteriocins and show probiotic potential, while others carry virulence factors and multidrug resistance, acting as opportunistic pathogens. This duality highlights the importance of comprehensive evaluation. Creative Biolabs' E. faecalis microbiome CRO service provides end-to-end solutions, including isolation, functional characterization, host-interaction studies, and biosafety assessments. Our expertise enables clients to de-risk E. faecalis research, accelerate discovery, and gain actionable insights into its microbiome functions.
We employ optimized culturing techniques to isolate E. faecalis from complex samples (such as fecal matter or environmental swabs) and obtain pure colonies. Our team then performs initial screening of isolates, including Gram staining and genotypic confirmation, to verify species identity. We also evaluate colony morphology and basic phenotypic traits to select robust E. faecalis strains for downstream analyses, providing a solid foundation of high-quality isolates for your research.
Creative Biolabs offers comprehensive antibiotic susceptibility profiling for E. faecalis strains. Using standardized assays (e.g. broth microdilution and disk diffusion), we determine the minimum inhibitory concentrations of various antibiotics and chart the resistance/susceptibility profile of each strain. This is especially important given the rise of vancomycin-resistant E. faecalis isolates in recent years. Our detailed reports identify any antibiotic resistance genes or phenotypes present, helping researchers understand safety concerns and informing the development of new antimicrobial strategies.
We conduct extensive functional assays to uncover the biochemical activities and potential mechanisms of action (MoA) of E. faecalis strains. These screenings include tests for metabolic capabilitiesand beneficial functions like bile salt tolerance, short-chain fatty acid production, or bacteriocin secretion. We also examine antagonistic activity against pathogens and other microbiota members. By elucidating E. faecalis' functional attributes, our service helps pinpoint how a strain exerts its effects within the microbiome and provides clues to its probiotic potential or pathogenic mechanisms.
Understanding how E. faecalis interacts with host tissues is key to gauging its safety and efficacy. We offer in vitro host-microbe interaction assays, including adhesion studies with intestinal epithelial cell lines and gut barrier integrity tests. For example, we can quantify E. faecalis' ability to adhere to mucosal surfaces or its effect on tightening or loosening of epithelial junctions. We also assess cross-talk with host signaling pathways by measuring changes in epithelial cell responses upon co-culture.
Our scientists evaluate the immunomodulatory properties of E. faecalis using specialized cell-based assays. We incubate live E. faecalis with immune cells such as human peripheral blood mononuclear cells or macrophage/DC cultures. By monitoring cytokine production (e.g. levels of IL-10, IL-12, TNF-α) and immune cell activation markers, we determine whether a given E. faecalis strain induces pro-inflammatory or anti-inflammatory responses. These in vitro immune modulation tests are crucial for identifying strains that could be beneficial versus those that trigger undesirable immune reactions.
Creative Biolabs provides fermentation process development tailored to E. faecalis. Thanks to their tolerance to a range of pH and temperature condition, E. faecalis strains can be cultured at scale efficiently. We optimize growth media and bioreactor parameters to maximize biomass and maintain strain viability and functionality. Whether you require small pilot batches or larger quantities, our fermentation experts ensure a consistent, high-yield production of E. faecalis. This service is invaluable for generating sufficient material for animal studies, formulation trials, or further product development.
After culturing the bacteria, we also support the formulation of E. faecalis as a stable product for research use. Our formulation services include concentration and purification of the cultured bacteria, followed by processes such as lyophilization (freeze-drying) to create a shelf-stable powder. We carefully select cryoprotectants and excipients that preserve cell viability and activity during storage. Additionally, we can formulate E. faecalis into capsules, suspensions, or other delivery formats as needed for your experimental design.
We offer a battery of safety evaluations for E. faecalis strains to ensure they are suitable for research. Our safety tests include checking for known virulence factors and toxin production, assessing hemolytic activity on blood agar, and measuring undesirable metabolites like biogenic amines. We also confirm the absence of transferable antibiotic resistance genes to avoid propagating dangerous traits. For example, a strain intended as a probiotic candidate should show no hemolysis, no toxin gene sequences, and be susceptible to standard antibiotics. By thoroughly screening each strain, Creative Biolabs helps you meet regulatory guidelines and ensures E. faecalis is handled with appropriate biosafety precautions.
Define research objectives, select assays, and design tailored E. faecalis study protocols.
Process samples, selectively culture E. faecalis, and confirm identity using molecular characterization.
Conduct antimicrobial susceptibility, metabolic analysis, and functional screening for detailed strain characterization.
Evaluate adhesion, barrier integrity, and immune modulation in host-microbe interaction assays.
Scale up biomass production, optimize conditions, and prepare stable research-grade formulations.
Analyze experimental results, generate detailed reports, and provide expert scientific interpretation support.
Experienced microbiome scientists ensure precise E. faecalis research design, execution, and data interpretation for reliable outcomes.
From isolation to safety assessment, we provide complete, integrated solutions covering every stage of E. faecalis research.
Cutting-edge genomic, proteomic, and metabolomic platforms enable high-resolution characterization of E. faecalis properties and microbiome interactions.
Stringent protocols and safety evaluations guarantee consistent data quality, reliability, and regulatory compliance throughout every project stage.
Flexible workflows allow tailored assay selection and protocol modifications to precisely address unique research requirements.
Dedicated experts provide ongoing communication, technical consultation, and project updates to strengthen client partnerships and scientific progress.
E. faecalis serves as a model to investigate microbial ecology, host interactions, and community dynamics, providing insights into microbiome balance, dysbiosis, and overall gastrointestinal health outcomes.
Certain E. faecalis strains show functional benefits such as bacteriocin production or immune modulation, supporting their evaluation as potential probiotic candidates under rigorous laboratory conditions for research purposes.
With rising vancomycin-resistant Enterococci, E. faecalis enables detailed investigations into resistance mechanisms, testing of novel antimicrobials, and development of effective control strategies against multidrug-resistant bacterial strains.
Higher abundance of E. faecalis in IBD patients highlights its role in gut inflammation, supporting mechanistic studies into epithelial barrier disruption and immune dysregulation in disease.
As an opportunistic pathogen, E. faecalis is studied for virulence factors and biofilm formation, advancing infection biology understanding and strategies for hospital-associated infection prevention and management.
E. faecalis strains influence immune responses, enabling research on cytokine production, T-cell regulation, and innate immunity to reveal host tolerance versus inflammation mechanisms in microbial interactions.
To further support E. faecalis projects, Creative Biolabs also provides a range of related research products:
Product Name | Catalog No. | Target | Product Overview | Size | Price |
---|---|---|---|---|---|
Enterococcus faecalis | LBGF-0722-GF21 | Enterococcus | Gram-positive commensal bacterium inhabiting the gastrointestinal tracts of humans. It is found in healthy humans and can be used as a probiotic. | — | |
Heat inactivated Enterococcus faecalis | LBGF-0224-GF45 | Inactivated Enterococcus | Heat-inactivated at 65 °C for 30 min; frozen format; shipping on dry ice. | — | |
Enterococcus faecalis, Rabbit faeces | LBGF-0323-GF1 | Enterococcus | Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans. It is found in healthy humans and can be used as a probiotic. | — | |
Enterococcus faecalis DNA Standard | LBGF-0125-GF3 | Enterococcus DNA Standard | Microbial DNA standard from Enterococcus faecalis. | — | |
Inactivated Enterococcus faecalis, 1 mL | LBGF-0125-GF147 | Inactivated Enterococcus | Enterococcus faecalis has been inactivated. | 1 mL | |
Enterococcus faecalis DNA Standard; 100 μL/vial | LBGF-0125-GF43 | Enterococcus DNA Standard | Be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control. | 100 µL/vial; 5 |
We perform rigorous identification of isolates using a combination of methods. After selective culturing, we verify E. faecalis via Gram-staining (Gram-positive cocci) and biochemical tests, and we confirm species identity by 16S rRNA gene sequencing or MALDI-TOF mass spectrometry. This polyphasic approach ensures the accuracy of our strain identification.
Absolutely. We tailor each project to the client’s goals. Researchers can select specific assays from our service portfolio or request custom protocol adjustments. Our experts collaborate closely with you to design a workflow that addresses your particular scientific questions, whether it’s focusing on a certain virulence factor, testing a novel compound, or any other specialized requirement.
Our E. faecalis service package includes comprehensive safety testing. We screen strains for harmful attributes such as hemolysin production, gelatinase activity, and toxin genes. We also perform antibiotic susceptibility tests and check for known antibiotic resistance genes. If a strain exhibits any unsafe characteristics (for example, high virulence or multi-drug resistance), we flag it in our report. These evaluations ensure that only strains suitable for research progress through development.
No – our services are for research use only. Creative Biolabs specializes in preclinical research support. We do not provide clinical treatments or diagnostics. All E. faecalis studies and products we handle are intended to advance scientific understanding or aid in the R&D of future therapeutics, but they are not themselves clinical or therapeutic offerings.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2025 Creative Biolabs. All Rights Reserved.